Popov Vladimir M, Wang Chenguang, Shirley L Andrew, Rosenberg Anne, Li Shengwen, Nevalainen Marja, Fu Maofu, Pestell Richard G
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, Philadelphia, PA 19107, United States.
Steroids. 2007 Feb;72(2):221-30. doi: 10.1016/j.steroids.2006.12.001. Epub 2007 Feb 7.
The endocrine signaling governing nuclear receptor (NR) function has been known for several decades to play a crucial role in the onset and progression of several tumor types. Notably among these are the estrogen receptor (ER) in breast cancer and androgen receptor (AR) in prostate cancer. Other nuclear receptors may be involved in cancer progression including the peroxisome-proliferator activating receptor gamma (PPARgamma), which has been implicated in breast, thyroid, and colon cancers. These NR are phylogenetically conserved modular transcriptional regulators, which like histones, undergo post-translational modification by acetylation, phosphorylation and ubiquitination. Importantly, the transcriptional activity of the receptors is governed by the coactivator p300, the activity of which is thought to be rate-limiting in the activity of these receptors. Histone acetyltransferases (HATs) and histone deacetylases (HDACs), modify histones by adding or removing an acetyl group from the epsilon amino group of lysines within an evolutionarily conserved lysine motif. Histone acetylation results in changes in chromatin structure in response to specific signals. These enzymes can also directly catalyze the NRs themselves, thus modifying signals at the receptor level. The post-translational modification of NR which is regulated by hormones, alters the NR function toward a growth promoting receptor. The deacetylation of NR is mediated by TSA-sensitive and NAD-dependent deacetylases. The regulation of NR by NAD-dependent enzymes provides a direct link between intracellular metabolism and hormone signaling.
几十年来,人们已知调控核受体(NR)功能的内分泌信号在多种肿瘤类型的发生和发展中起着关键作用。其中特别值得注意的是乳腺癌中的雌激素受体(ER)和前列腺癌中的雄激素受体(AR)。其他核受体可能也参与癌症进展,包括过氧化物酶体增殖物激活受体γ(PPARγ),它与乳腺癌、甲状腺癌和结肠癌有关。这些核受体是系统发育保守的模块化转录调节因子,与组蛋白一样,会通过乙酰化、磷酸化和泛素化进行翻译后修饰。重要的是,受体的转录活性由共激活因子p300调控,其活性被认为是这些受体活性的限速因素。组蛋白乙酰转移酶(HATs)和组蛋白去乙酰化酶(HDACs)通过在进化保守的赖氨酸基序内的赖氨酸ε氨基上添加或去除乙酰基来修饰组蛋白。组蛋白乙酰化会响应特定信号导致染色质结构发生变化。这些酶也可以直接催化核受体本身,从而在受体水平上改变信号。由激素调控的核受体翻译后修饰会使核受体功能朝着促生长受体转变。核受体的去乙酰化由TSA敏感和NAD依赖的去乙酰化酶介导。NAD依赖的酶对核受体的调控在细胞内代谢和激素信号之间建立了直接联系。